


Anti-Human HLA-DR Purified

Catalog Number: 14-9956

Also Known As:

RUO: For Research Use Only. Not for use in diagnostic procedures.



Staining of normal human peripheral blood cells with 0.125 ug of Purified Mouse IgG2b Isotype Control (cat. 14-4732) (open histogram) or 0.125 ug of Anti-Human HLA-DR Purified) (filled histogram) followed by Anti-Mouse IgG FITC (cat. 11-4011). Cells in the lymphocyte gate were used for analysis.

Product Information

Contents: Anti-Human HLA-DR Purified

REF **Catalog Number:** 14-9956

Clone: LN3

Concentration: 0.5 mg/ml

Host/Isotype: Mouse IgG2b, kappa

Formulation: aqueous buffer, 0.09% sodium azide, may contain carrier protein/stabilizer



Temperature Limitation: Store at 2-8°C.



Batch Code: Refer to Vial



Use By: Refer to Vial



Caution, contains Azide

Description

The LN3 mAb reacts with the human major histocompatibility complex (MHC) class II, HLA-DR. HLA-DR is expressed on the surface of human antigen presenting cells (APC) including B cells, monocytes, macrophages, DCs, and activated T cells. HLA-DR is a heterodimeric transmembrane protein composed of α and β subunits and plays an important role in the presentation of peptides to CD4⁺ T lymphocytes.

Applications Reported

The LN3 antibody has been reported for use in flow cytometric analysis, and immunohistochemical staining. Immunohistochemistry can be performed using frozen and Bouin's, or formalin/paraffin, human tissues.

Applications Tested

The LN3 antibody has been tested by flow cytometric analysis of human peripheral blood leukocytes. This can be used at less than or equal to 0.125 μ g per test. A test is defined as the amount (μ g) of antibody that will stain a cell sample in a final volume of 100 μ L. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.

References

Fullen, D. R. and J. T. Headington. 1998. Factor XIIIa-positive dermal dendritic cells and HLA-DR expression in radial versus vertical growth-phase melanomas. *J Cutan Pathol.* 25(10): 553-8.

Hua, Z. X., K. E. Tanaka, et al. 1998. Immunoreactivity for LN2 and LN3 distinguishes small cell carcinomas from non-small cell carcinomas in the lung. *Hum Pathol.* 29(12): 1441-6.

Ioachim, H. L., S. E. Pambuccian, et al. 1996. Lymphoid monoclonal antibodies reactive with lung tumors. Diagnostic applications. *Am J Surg Pathol.* 20(1): 64-71.

Davey, F. R., S. Olson, et al. 1988. The immunophenotyping of extramedullary myeloid cell tumors in paraffin-embedded tissue sections. *Am J Surg Pathol.* 12(9): 699-707.

Norton, A. J. and P. G. Isaacson. 1987. Detailed phenotypic analysis of B-cell lymphoma using a panel of antibodies reactive in routinely fixed wax-embedded tissue. *Am J Pathol.* 128(2): 225-40.

Related Products

11-4011 Anti-Mouse IgG FITC

11-4317 Streptavidin FITC
12-4317 Streptavidin PE
13-4013 Anti-Mouse IgG Biotin (Polyclonal)
14-4732 Mouse IgG2b K Isotype Control Purified
17-4317 Streptavidin APC

Not for further distribution without written consent.

Copyright © 2000-2010 eBioscience, Inc.

Tel: 888.999.1371 or 858.642.2058 • Fax: 858.642.2046 • www.eBioscience.com • info@eBioscience.com